Shots: Wuxi to receive upfront, $450M milestone and royalties on sales from Oxford BioTherapeutics. Oxford to get rights for WuXi Biologics’ WuXiBody platform to develop and commercialize five Bispecific Abs for cancer The focus […]readmore
Tags : WuXiBody Platform